FGF2 and mesothelioma: In line with this, it was shown that antiproliferative effects of the multikinase inhibitor sorafenib were most pronounced in tumor-initiating mesothelioma cells which expressed high levels of FGF2, leading to autocrine activation of FGFR1 [37].